This Article Full Text Full Text (PDF) All Versions of this Article: 149/1/146    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Galli, C. Articles by O’Brien, C. A. Search for Related Content PubMed PubMed Citation Articles by Galli, C. Articles by O’Brien, C. A. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB PARATHYROID HORMONE

Targeted Deletion of a Distant Transcriptional Enhancer of the Receptor Activator of Nuclear Factor-B Ligand Gene Reduces Bone Remodeling and Increases Bone Mass

Center for Osteoporosis and Metabolic Bone Diseases (C.G., Q.F., R.S.W., S.C.M., C.A.O.), University of Arkansas for Medical Sciences, and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72205; and Department of Biochemistry (L.A.Z., J.A.F., J.W.P.), University of Wisconsin-Madison, Madison, Wisconsin 53706

Address all correspondence and requests for reprints to: Charles A. O’Brien, University of Arkansas for Medical Sciences, 4301 West Markham Street, MS 587, Little Rock, Arkansas 72205. E-mail: caobrien{at}uams.edu.

Receptor activator of nuclear factor-B ligand (RANKL) is essential for osteoclast differentiation, and hormones and cytokines that stimulate bone resorption increase RANKL expression in stromal/osteoblastic cells. We have previously shown that PTH and 1,25-dihydroxyvitamin D₃ control murine RANKL gene expression in vitro, in part, via an evolutionarily conserved transcriptional enhancer, designated the distal control region (DCR), located 76 kb upstream from the transcription start site. Herein we describe the phenotype of mice lacking this enhancer. Deletion of the DCR reduced PTH and 1,25-dihydroxyvitamin D₃ stimulation of RANKL mRNA and osteoclast formation in primary bone marrow cultures as well as stimulation of RANKL mRNA in bone. DCR deletion also reduced basal RANKL mRNA levels in bone, thymus, and spleen. Moreover, mice lacking the DCR exhibited increased bone mass and strength. The increase in bone mass was due to reduced osteoclast and osteoblast formation leading to a low rate of bone remodeling similar to that observed in humans and mice with hypoparathyroidism. These findings demonstrate that hormonal control of RANKL expression via the DCR is a critical determinant of the rate of bone remodeling.